InMed Pharmaceuticals (INM) Other Non-Current Liabilities (2020 - 2021)
InMed Pharmaceuticals (INM) posted quarterly Other Non-Current Liabilities of $1.8 million for Q1 2021, little changed quarter-over-quarter from $1.8 million in Q4 2020.
InMed Pharmaceuticals (INM) Other Non-Current Liabilities (2020 - 2021) Analysis & Trends
InMed Pharmaceuticals' Other Non-Current Liabilities history runs 2 years deep, the most recent figure standing at $1.8 million for Q1 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - |
| 10 | InMed Pharmaceuticals | 6.44 Mn | 1.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2021 | 1.76 Mn |
| Dec 31, 2020 | 1.76 Mn |